Circulating levels of Elabela and Apelin in the second and third trimesters of pregnancies with gestational diabetes mellitus

Gynecol Endocrinol. 2020 Oct;36(10):890-894. doi: 10.1080/09513590.2020.1739264. Epub 2020 Mar 25.

Abstract

We design this study to detect levels of Elabela (ELA) and Apelin (APLN) in women with and without gestational diabetes mellitus (GDM) in the second and third trimesters, and to identify whether there is any association between ELA, APLN, and metabolic parameters. Seventy-nine GDM and 80 control subjects in the second trimester and 87 GDM and 88 healthy subjects in the third trimester were included. In the second trimester, lower ELA levels [(14.1 versus 16.9) ng/ml, p = .025] and higher APLN levels [(1021.8 versus 923.5) pg/ml, p = .046] were observed in GDM patients compared to controls. ELA levels were positively correlated with fasting plasma glucose (FPG) (r = 0.423, p < .001) in the control group, and APLN levels were negatively correlated with triglycerides (TG) (r = -0.251, p = .025) in the control group and total cholesterol (TC) (r = -0.227, p = .044) in the GDM group. ELA appeared to be related to glucose metabolism and APLN is involved in lipid metabolism during pregnancy. The expression of ELA is significantly downregulated from the second trimester to the third trimester.

Keywords: Apelin; Elabela; Gestational diabetes mellitus; glucose metabolism; lipid metabolism.

MeSH terms

  • Adult
  • Apelin / blood*
  • Case-Control Studies
  • Diabetes, Gestational / blood*
  • Female
  • Humans
  • Peptide Hormones / blood*
  • Pregnancy
  • Pregnancy Trimester, Second / blood
  • Pregnancy Trimester, Third / blood

Substances

  • APELA protein, human
  • Apelin
  • Peptide Hormones